Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.8%

1 terminated/withdrawn out of 21 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

29%

6 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
8(44.4%)
Phase 3
6(33.3%)
N/A
3(16.7%)
Phase 1
1(5.6%)
18Total
Phase 2(8)
Phase 3(6)
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT04930744Phase 2Completed

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Role: collaborator

NCT06548035Not ApplicableCompleted

Developing a Resiliency Intervention to Support Healthcare Workers Engaged in the Provision of HIV Care

Role: collaborator

NCT07379203Phase 2Not Yet Recruiting

ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse

Role: lead

NCT07163143Phase 3Not Yet Recruiting

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

Role: collaborator

NCT05175794Completed

Triage Test for All Oral DR-TB Regimen (TRiAD Study)

Role: collaborator

NCT05686356Phase 2Active Not Recruiting

A Pan-TB Regimen Targeting Host and Microbe

Role: collaborator

NCT06277141Not ApplicableCompleted

The Vitality Mammography Messaging Study

Role: lead

NCT04975178Phase 3Recruiting

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

Role: collaborator

NCT04567368Active Not Recruiting

TB-CAPT MTB/XDR Study

Role: collaborator

NCT04062201Phase 3Completed

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

Role: lead

NCT03942354Completed

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

Role: collaborator

NCT02589782Phase 2Completed

Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

Role: collaborator

NCT04207112Phase 2Completed

Economic Evaluation of New MDR TB Regimens

Role: collaborator

NCT06133686Phase 3Not Yet Recruiting

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

Role: collaborator

NCT05755555Not ApplicableUnknown

Testing the Effectiveness of Different Messaging Approaches to Increase Doctor Visits Amongst Individuals With Risk Factors for Diabetes

Role: lead

NCT03986970Phase 2Completed

The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention

Role: lead

NCT04581915Phase 2Terminated

PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19

Role: lead

NCT05148845Phase 3Unknown

Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Role: lead

NCT04838795Phase 3Completed

Sisonke (Together): OPEN LABEL TRIAL COVID-19

Role: lead

NCT04081077Phase 2Unknown

PRACTECAL-PKPD Sub Study

Role: collaborator